KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Receivables: 2010-2025

Historic Receivables for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $115.3 million.

  • Pacira BioSciences' Receivables rose 14.52% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.7 million, marking a year-over-year increase of 8.50%. This contributed to the annual value of $113.3 million for FY2024, which is 7.34% up from last year.
  • Pacira BioSciences' Receivables amounted to $115.3 million in Q3 2025, which was up 0.79% from $114.4 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Receivables ranged from a high of $115.3 million in Q3 2025 and a low of $50.0 million during Q3 2021.
  • Moreover, its 3-year median value for Receivables was $104.7 million (2025), whereas its average is $104.5 million.
  • In the last 5 years, Pacira BioSciences' Receivables surged by 87.04% in 2022 and then dropped by 1.20% in 2023.
  • MRQ analysis of 5 years shows Pacira BioSciences' Receivables stood at $96.3 million in 2021, then increased by 2.16% to $98.4 million in 2022, then rose by 7.28% to $105.6 million in 2023, then increased by 7.34% to $113.3 million in 2024, then rose by 1.73% to $115.3 million in 2025.
  • Its Receivables was $115.3 million in Q3 2025, compared to $114.4 million in Q2 2025 and $104.7 million in Q1 2025.